<DOC>
	<DOC>NCT01330381</DOC>
	<brief_summary>To evaluate the efficacy of prucalopride compared to placebo for the treatment of functional constipation in a paediatric population, aged ≥ 6 months to &lt; 18 years. A 16-week open-label comparator (PEG) controlled part will follow, to document safety and tolerability up to 24 weeks.</brief_summary>
	<brief_title>Prucalopride in Pediatric Subjects With Functional Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Main 1. Boys and girls, aged ≥ 6 months and &lt; 18 years. 2. Subjects with a confirmed diagnosis of functional constipation as defined by the Rome III criteria. Main 1. Children with underlying GI abnormalities and causes for defecation disorders. 2. Constipation is thought to be druginduced. 3. Subjects suffering from secondary causes of chronic constipation.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>